Trevi Therapeutics
New Haven
Connecticut
United States
Tel: 203-304-2499
Fax: 203-304-2434
Website: http://www.trevitherapeutics.com/
Email: info@trevitherapeutics.com
140 articles about Trevi Therapeutics
-
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
3/13/2024
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that senior management will host a conference call and live audio webcast on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2023.
-
Trevi Therapeutics to Participate in Upcoming March Events
2/28/2024
Trevi Therapeutics, Inc today announced that senior management will attend and participate in the following events in March.
-
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Trevi Therapeutics, Inc. today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET.
-
Trevi Therapeutics Provides Business Updates
1/4/2024
Trevi Therapeutics, Inc. today announced a preview of business updates.
-
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
12/5/2023
Trevi Therapeutics, Inc. today announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough.
-
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, today announced financial results for the quarter ended September 30, 2023, as well as provided business updates.
-
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
11/2/2023
Trevi Therapeutics, Inc. announced the initiation of its Phase 2a RIVER clinical trial evaluating Haduvio in RCC patients.
-
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
11/1/2023
Trevi Therapeutics, Inc. announced that senior management will host a conference call and live audio webcast on Thursday, November 9, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2023.
-
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
10/13/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced the 52-week results from its phase 2b/3 PRISM open-label extension (OLE) study of Haduvio for the treatment of prurigo nodularis.
-
Trevi Therapeutics to Participate in Upcoming September Events
9/6/2023
Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following events in September.
-
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
8/10/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates.
-
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
8/3/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that senior management will host a conference call and live audio webcast on Thursday, August 10, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2023.
-
Trevi Therapeutics to Participate in Upcoming August Events
8/1/2023
Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following events in August.
-
Trevi Therapeutics to Participate in Upcoming July Investor Events
7/6/2023
Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following investor events in July.
-
Trevi Therapeutics to Participate in Upcoming June Conferences
5/30/2023
Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following conferences in June.
-
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
5/22/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced the positive results from the Phase 2 CANAL trial in adults with IPF chronic cough has been published in NEJM Evidence.
-
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter ended March 31, 2023, as well as provided business updates.
-
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
5/9/2023
Trevi Therapeutics, Inc. today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management.
-
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
5/4/2023
Trevi Therapeutics, Inc. announced that senior management will host a conference call and live audio webcast on Thursday, May 11, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2023.
-
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
5/2/2023
Trevi Therapeutics, Inc. today announced data will be presented from two scientific abstracts on the phase 2 CANAL trial in IPF chronic cough at the ATS 2023 International Conference, organized by the American Thoracic Society, being held in Washington, D.C. from May 19-24. The oral presentations will take place on May 22.